- Home
- ABUS vs KIO Comparison
ABUS vs KIO Comparison
Compare ABUS & KIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- KIO
- Stock Information
- Founded
- ABUS 2005
- KIO 2011
- Country
- ABUS United States
- KIO United States
- Employees
- ABUS N/A
- KIO 2400
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- KIO Investment Managers
- Sector
- ABUS Health Care
- KIO Finance
- Exchange
- ABUS Nasdaq
- KIO Nasdaq
- Market Cap
- ABUS 611.0M
- KIO 514.6M
- IPO Year
- ABUS N/A
- KIO N/A
- Fundamental
- Price
- ABUS $3.22
- KIO $12.63
- Analyst Decision
- ABUS Strong Buy
- KIO
- Analyst Count
- ABUS 4
- KIO 0
- Target Price
- ABUS $5.50
- KIO N/A
- AVG Volume (30 Days)
- ABUS 774.3K
- KIO 136.5K
- Earning Date
- ABUS 08-04-2025
- KIO 01-01-0001
- Dividend Yield
- ABUS N/A
- KIO 10.82%
- EPS Growth
- ABUS N/A
- KIO N/A
- EPS
- ABUS N/A
- KIO N/A
- Revenue
- ABUS $6,403,000.00
- KIO N/A
- Revenue This Year
- ABUS $3.35
- KIO N/A
- Revenue Next Year
- ABUS N/A
- KIO N/A
- P/E Ratio
- ABUS N/A
- KIO N/A
- Revenue Growth
- ABUS N/A
- KIO N/A
- 52 Week Low
- ABUS $2.71
- KIO $10.52
- 52 Week High
- ABUS $4.73
- KIO $13.59
- Technical
- Relative Strength Index (RSI)
- ABUS 48.90
- KIO 60.79
- Support Level
- ABUS $3.08
- KIO $12.54
- Resistance Level
- ABUS $3.30
- KIO $12.81
- Average True Range (ATR)
- ABUS 0.10
- KIO 0.08
- MACD
- ABUS 0.01
- KIO -0.01
- Stochastic Oscillator
- ABUS 50.00
- KIO 51.35
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About KIO KKR Income Opportunities Fund
KKR Income Opportunities Fund operates as a closed-end registered management investment company. It seeks to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in the portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.